MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma

References

• Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer review: presentation and investigation of thyroid cancer. Int J Clin Pract. 2005;59:1459–1463. doi:10.1111/j.1368-5031.2005.00672.x16351679
   PubMed Web of Science ®Google Scholar
• Shanghai Municipal Center for Disease Control & Prevention. The incidence of malignant tumor in Shanghai in 2006. Tumor. 2010;29:918.
   Google Scholar
• Davies L, Welch HG. Increasing of thyroid cancer in The United States, 1973–2002. JAMA. 2006;295:2164–2167. doi:10.1001/jama.295.18.216416684987
   PubMed Web of Science ®Google Scholar
• Perigny M, Bairati I, Harvey I. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-1 1 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 2008;129:226–231. doi:10.1309/49LA9XCBGWJ8F2KM18208802
   PubMed Web of Science ®Google Scholar
• Velinov N, Poptodorov G, Gabrovski N. The role of matrixmetalloproteinases in the tumor growth and metastasis. Khirurgiia (Sofiia). 2010;1:44–49.
   Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29(5 ):290–308. doi:10.1016/j.mam.2008.05.00218619669
   PubMed Web of Science ®Google Scholar
• Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903. doi:10.1038/sj.bjc.660366617342087
   PubMed Web of Science ®Google Scholar
• Hojila CV, Wood GA, Khoka R. Metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008;10:205. doi:10.1186/bcr198018394187
   PubMed Web of Science ®Google Scholar
• Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20(5 ):749. doi:10.1093/carcin/20.5.74910334190
   PubMed Web of Science ®Google Scholar
• Patel A, Straight AM, Mann H, et al. Matrix metalloproteinase (MMPs) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest. 2002;25:403–408. doi:10.1007/BF0334402812035934
   PubMed Web of Science ®Google Scholar
• Ahmed M, Uddin S, Hussain AR, et al. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(1 ):1503–1516. doi:10.1210/jc.2011-1506
   Web of Science ®Google Scholar
• Zhang B, Li H, Yang YS, et al. Advances in the relationship between matrix metalloproteinases and their inhibitors and breast cancer. Chin J Lab Diagn. 2013;17(18 ):1534–1536.
   Google Scholar
• Zhou XF, Miao L, Mao WZ. Correlations between peripheral blood levels of matrix metalloproteinases and its inhibitors and thyroid carcinoma. Chin J Cancer Prev Treat. 2013;20(12 ):942–944.
   Google Scholar
• Anand M, Van Meter TE, Fillmore HL. Epidermal growth factor induces matrix metalloproteinase-1 (MMP-1) expression and invasion in glioma cell lines via the MAPK pathway. J Neurooncol. 2011;104(3 ):679–687. doi:10.1007/s11060-011-0549-x21359852
   PubMed Web of Science ®Google Scholar
• Li J, Ma JM. Research progress in matrix metalloproteinase-2,9 in gastric cancer. Chin Cancer. 2015;24(5 ):403–407.
   Google Scholar
• Miao JT, Wang SY, Wang Y, et al. Positive expression rates of HMGB1 and MMP-9 in endometrial carcinoma and correlation analysis. Maternal Child Health Care China. 2017;32(13 ):3036–3039.
   Google Scholar
• Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004;98(2 ):173–177. doi:10.1016/j.rmed.2003.08.01414971882
   PubMed Web of Science ®Google Scholar
• Zhao JX, Yang LP, Wang YF, et al. Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells. Eur J Neurol. 2007;14(5 ):510–517. doi:10.1111/ene.2007.14.issue-517437609
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu XK, Huang X, et al. Expression and role of matrix metalloproteinase-9 and osteopontin in thyroid carcinoma and thyroid benign tumor. Chin J Exp Surg. 2015;32(1 ):151–153.
   Google Scholar
• Zhang JJ, Liu ZM. Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in thyroid carcinoma tissue and their concentrations in serum. Chin J Bases Clin General Surg. 2007;14(4 ):437–441.
   Google Scholar
• Pasieka Z, Stepien H, Czyz W, et al. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumors treated surgically. Endocr Regul. 2004;38(2 ):112–116.
   Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8 ):827–839. doi:10.1161/01.RES.0000070112.80711.3D12730128
   PubMed Web of Science ®Google Scholar
• Lanmbert E, Dasse E, Haye B, et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematal. 2004;49(3 ):187–198. doi:10.1016/j.critrevonc.2003.09.008
   PubMed Web of Science ®Google Scholar
• Delektorskaia W, Smirnova EA, Ponomareva MV, et al. Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor. Arkh Patol. 2010;72(4 ):3–6.
   Google Scholar
• Islekel H, Oktay G, Terzi C, et al. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables. Cell Biochem Funct. 2007;27(4 ):433–441. doi:10.1002/cbf.1325
   Google Scholar
• Cho Mar K, Eimoto T, Tateyama H, et al. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology. 2006;48(3 ):286–294. doi:10.1111/j.1365-2559.2005.02325.x16430475
   PubMed Web of Science ®Google Scholar
• Rapti M, Knauper V, Murphy G, et al. Characterization of the AB loop region of TIMP-2 Involvement in pro-MMP-2 activation[J]. J Biol Chem. 2006;281(33):23386–23394. doi:10.1074/jbc.M604423200.
   PubMedGoogle Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:1–33. doi:10.1089/thy.2006.16.10916487007
   PubMed Web of Science ®Google Scholar
• Waveren CV, Sun YB, Cheung HS, et al. Oxidative phosphorylation dysfunction modulates expression of extracellular matrix—remodeling genes and invasion. Carcinogenesis. 2006;27(3 ):409–418. doi:10.1093/carcin/bgi24216221732
   PubMed Web of Science ®Google Scholar